Effect of "Jollab-e-monzej" for the treatment of MS-related fatigue

Efficacy and safety of “Jollab monzej” as a traditional Persian compound medicine for the treatment of multiple sclerosis-related fatigue: A randomized placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190623043984N1

Enrollment

Registered

2020-01-10

Start date

2020-01-21

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Intervention group 1: Jollab-e-monzej syrup, which the participants consume in the morning and evening, 20 to 30 ml, depending on their weight, for one month. Inter

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: -Multiple sclerosis patients, female or male -Age range 18-55 years -Patients with relapsing-remitting MS -MS patients with EDSS of less than or equal to 6 -MS patients are suffering from fatigue and insomnia -Fatigue score greater than or equal to 36 on the FSS questionnaire -Consent to participate in the study

Exclusion criteria

Exclusion criteria: -Pregnancy and lactation -The comorbidity of severe and chronic disease -known active infection -Suffering from psychosis or dementia -Depression in BDI questionnaire -Patients with a change in main drug of MS over the past three months -Patients with relapse and/or consumption of corticosteroides over the past three months

Design outcomes

Primary

Measure	Time frame
Fatigue score on the fatigue severity scale questionnaire. Timepoint: Measurement of fatigue score at baseline and after one month (intervention period) and also two weeks after intervention period. Method of measurement: Fatigue severity scale questionnaire.	—

Secondary

Measure	Time frame
Fatigue score on the visual analogue score. Timepoint: Measurement of fatigue score at baseline and after one month (intervention period) and also two weeks after intervention period. Method of measurement: The Visual analogue scale (VAS).;Global sleep quality score on the PSQI questionnaire. Timepoint: Measurement of global sleep quality score at baseline and after one month (intervention period) and also two weeks after intervention period. Method of measurement: The Pittsburgh Sleep Quality Index (PSQI).;Depression score on BDI questionnaire. Timepoint: Measurement of depression score at baseline and after one month (intervention period) and also two weeks after intervention period. Method of measurement: Beck depression inventory questionnaire (BDI).	—

Measure

Time frame

Fatigue score on the visual analogue score. Timepoint: Measurement of fatigue score at baseline and after one month (intervention period) and also two weeks after intervention period. Method of measurement: The Visual analogue scale (VAS).;Global sleep quality score on the PSQI questionnaire. Timepoint: Measurement of global sleep quality score at baseline and after one month (intervention period) and also two weeks after intervention period. Method of measurement: The Pittsburgh Sleep Quality Index (PSQI).;Depression score on BDI questionnaire. Timepoint: Measurement of depression score at baseline and after one month (intervention period) and also two weeks after intervention period. Method of measurement: Beck depression inventory questionnaire (BDI).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Yousefnia Babaki

Shahid Beheshti University of Medical Sciences

fyousefnia@sbmu.ac.ir+98 21 8877 3521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026